The Use of Ascorbic Acid in Adjunctive Treatment for Schizophrenia-Current State of Knowledge

被引:1
|
作者
Pilat, Patrycja [1 ]
Nikel, Kamil [1 ]
Smolarczyk, Joanna [2 ]
Piegza, Magdalena [3 ]
机构
[1] Med Univ Silesia, Fac Med Sci Zabrze, Dept Psychiat, Students Sci Assoc, PL-40055 Katowice, Poland
[2] Med Univ Silesia, Dept Psychoprophylaxis, PL-40055 Katowice, Poland
[3] Med Univ Silesia, Fac Med Sci Zabrze, Dept Psychiat, PL-40055 Katowice, Poland
来源
LIFE-BASEL | 2024年 / 14卷 / 07期
关键词
schizophrenia; ascorbic acid; vitamin C; clozapine; VITAMIN-C; OXIDATIVE STRESS; ANTIPSYCHOTICS; CLOZAPINE; SUPPLEMENTATION; MODULATION; BEHAVIOR;
D O I
10.3390/life14070828
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Schizophrenia is a mental illness characterized by disturbances in the perception of reality, thinking, emotions, and social functioning. This significantly impacts the quality of life of patients and leads to long-term disability. Despite advances in understanding its pathogenesis and treatment, schizophrenia remains a clinical challenge, especially due to the diversity of its symptoms and the complexity of its mechanisms. Schizophrenia is associated with abnormal functioning of the dopaminergic system, disturbances in glutamatergic neurotransmission, and oxidative stress in the brain. In recent years, there has been increasing interest in optimizing the treatment of mental disorders. The potential use of ascorbic acid, or vitamin C, in the therapy of schizophrenia could bring substantial benefits to patients. Ascorbic acid exhibits antioxidant and neuroprotective properties, suggesting its potential efficacy in reducing brain oxidative stress and improving neurotransmission. Additionally, there have been reports of its positive effects on psychotic symptoms and its potential in reducing the side effects of antipsychotic drugs. In this review article, we present the current state of knowledge on the potential use of ascorbic acid in the treatment of schizophrenia as an adjunct to standard pharmacological therapy. We analyze existing clinical studies and the mechanisms of action of vitamin C, suggesting its promising role as an adjunctive therapy in the treatment of schizophrenia. These insights, though not yet widely disseminated, may be significant for the further development of therapeutic strategies for this mental illness.
引用
收藏
页数:11
相关论文
共 50 条
  • [1] AN ADJUNCTIVE ROLE FOR ASCORBIC-ACID IN THE TREATMENT OF SCHIZOPHRENIA
    BEAUCLAIR, L
    VINOGRADOV, S
    RINEY, SJ
    CSERNANSKY, JG
    HOLLISTER, LE
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 1987, 7 (04) : 282 - 283
  • [2] Azelaic acid in dermatological treatment - current state of knowledge
    Reszke, Radomir
    Szepietowski, Jacek
    PRZEGLAD DERMATOLOGICZNY, 2016, 103 (04): : 337 - 343
  • [3] DESOXYCORTONE ACETATE AND ASCORBIC ACID IN THE TREATMENT OF SCHIZOPHRENIA
    REES, L
    KING, GM
    JOURNAL OF MENTAL SCIENCE, 1951, 97 (407): : 376 - 380
  • [4] Adjunctive use of interferon γ inducer for treatment of patients with schizophrenia
    Vetlugina, Tamara Parfenovna
    Lobacheva, Olga Anatolyevna
    Sergeeva, Svetlana Alexandrovna
    Nikitina, Valentina Borisovna
    Nevidimova, Tatiana Ivanovna
    Semke, Arkady Valentinovich
    ACTA NEUROPSYCHIATRICA, 2016, 28 (03): : 149 - 156
  • [5] -Lipoic Acid as Adjunctive Treatment for Schizophrenia: An Open-Label Trial
    Olivier Sanders, Lia Lira
    de Souza Menezes, Carlos Eduardo
    Maia Chaves Filho, Adriano Jose
    Viana, Glautemberg de Almeida
    Fechine, Francisco Vagnaldo
    Rodrigues de Queiroz, Maria Goretti
    da Cruz Fonseca, Said Goncalvez
    Mendes Vasconcelos, Silvania Maria
    Amaral de Moraes, Maria Elisabete
    Gama, Clarissa S.
    Seybolt, Sheila
    Campos, Eugenio de Moura
    Macedo, Danielle
    de Lucena, David Freitas
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2017, 37 (06) : 697 - 701
  • [6] α-Lipoic Acid as Adjunctive Treatment for Schizophrenia A Randomized Double-Blind Study
    De Lima, David Nunes
    Costa Filho, Carlos Winston Luz
    Frota, Ilgner Justa
    de Oliveira, Alissandra Lima Barbosa
    de Souza Menezes, Carlos Eduardo
    Chaves Filho, Adriano Jose Maia
    de Almeida Viana, Glautemberg
    de Moura Campos, Eugenio
    Collares, Monica
    de Queiroz, Maria Goretti Rodrigues
    da Cruz Fonseca, Said Goncalvez
    Vasconcelos, Silvania Maria Mendes
    Macedo, Danielle S.
    Sanders, Lia Lira Olivier
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2023, 43 (01) : 39 - 45
  • [7] Effects of adjunctive pimavanserin and current antipsychotic treatment on QT interval prolongation in patients with schizophrenia
    Bugarski-Kirola, Dragana
    Nunez, Rene
    Odetalla, Ramzey
    Liu, I-Yuan
    Turner, Mary Ellen
    FRONTIERS IN PSYCHIATRY, 2022, 13
  • [8] CURRENT STATE OF THE PROBLEM OF SCHIZOPHRENIA (PSYCHOPATHOLOGY, CLASSIFICATION AND TREATMENT)
    Tiganov, A. S.
    ISRAEL JOURNAL OF PSYCHIATRY AND RELATED SCIENCES, 2012, 49 (01): : 40 - 40
  • [9] Balancing Potential Risks and Benefits of Adjunctive Use of Aripiprazole With Risperidone for the Treatment of Schizophrenia Reply
    Uchida, Hiroyuki
    Mamo, David C.
    JOURNAL OF CLINICAL PSYCHOPHARMACOLOGY, 2011, 31 (01) : 136 - 137
  • [10] Investigating the Effects of Adjunctive Transcranial Direct Current Stimulation on Treatment Adherence in Schizophrenia: Study Progress
    Song, Jianmeng
    Kim, Julia
    Kambari, Yasaman
    Amaev, Aron
    Ueno, Fumihiko
    Carmona, Edgardo Torres
    Abdolizadeh, Ali
    Koizumi, Teruki
    De Luca, Vincenzo
    Blumberger, Daniel M.
    Remington, Gary
    Pollock, Bruce
    Graff-Guerrero, Ariel
    Gerretsen, Philip
    BIOLOGICAL PSYCHIATRY, 2024, 95 (10) : S268 - S268